Why talk
- ZymoChem is already active in United States, where TIBOK wants to expand (traction: BAYSE in testing (home-use test in 2026, key ingredient produced at commercial scale)).
- TIBOK likely needs funding for the next round — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
- Complementary sectors: HealthTech × Biotech & life sciences — room for a joint offer or co-selling.
Score by goal: All goals 67 · Market entry 77 · Customers 49 · Investment 76 · Peers 56
Dimension by dimension
Needs ↔ offers
17.5 / 35 pts
ZymoChem can help TIBOK.
- TIBOK likely needs funding for the next round — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
Market bridge
25.0 / 25 pts
Direct bridge into a target market.
- ZymoChem is already active in United States, where TIBOK wants to expand (traction: BAYSE in testing (home-use test in 2026, key ingredient produced at commercial scale)).
- ZymoChem is based in United States (North America): a landing pad on another continent, both ways.
Customer potential
1.5 / 15 pts
No obvious buyer/seller or shared customer base.
Sector synergy
12.8 / 15 pts
Complementary sectors.
- Complementary sectors: HealthTech × Biotech & life sciences — room for a joint offer or co-selling.
Stage complementarity
10.0 / 10 pts
Strong mentoring / investor-intro potential.
- ZymoChem has raised about $25M — investor introductions are realistic.
- ZymoChem (Series A) is one step ahead of TIBOK (Seed) — the freshest playbook for TIBOK's next round.
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “All goals”: Needs ↔ offers 35, Market bridge 25, Customer potential 15, Sector synergy 15, Stage complementarity 10. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 64/100 — high from 50, medium from 36.